A comparison between low-magnitude voucher and buprenorphine medication contingencies in promoting abstinence from opioids and cocaine

Experimental and Clinical Psychopharmacology

Volumn 14, Issue 2, 2006, Pages 148-156

  Groß, Anke ^a,d   Marsch, Lisa A ^b   Badger, Gary J ^c   Bickel, Warren K ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF VERMONT   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d Outpatient Clinic for Neurology and Psychiatry   (Germany)

Author keywords

Behavioral therapy; Buprenorphine; Cocaine abstinence; Contingency management; Opioid abstinence

Indexed keywords

BUPRENORPHINE; COCAINE; ILLICIT DRUG; OPIATE DERIVATIVE;

ADULT; ARTICLE; BEHAVIOR THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; OPIATE ADDICTION; PATIENT COUNSELING; RANDOMIZED CONTROLLED TRIAL; STANDARD; TREATMENT OUTCOME; URINALYSIS;

ADULT; BEHAVIOR THERAPY; BUPRENORPHINE; COCAINE-RELATED DISORDERS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; REINFORCEMENT SCHEDULE;

EID: 33745596123     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.14.2.148     Document Type: Article

References (61)

1. Aickin, M. (1982). A program for balancing the allocation of subjects to treatment in a clinical trial. Computers and Biomedical Research, 15, 519-524.
2. Amass, L., Bickel, W. K., Crean, J. P., Blake, J., & Higgins, S. T. (1998). Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology, 136, 217-225.
3. Amass, L., Bickel, W. K., Higgins, S. T., & Badger, G. J. (1994). Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sciences, 54, 1215-1228.
4. Amass, L., & Kamien, J. (2004). A tale of two cities: Financing two voucher programs for substance abusers through community donations. Experimental and Clinical Psychopharmacology, 12, 147-155.
5. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
6. Baker, F., Johnson, M. W., & Bickel, W. K. (2003). Delay discounting in current and never-before cigarette smokers: Similarities and differences across commodity, sign, and magnitude. Journal of Abnormal Psychology, 112, 382-392.
7. Beck, A. T. (1978). Depression Inventory. Philadelphia: Center for Cognitive Therapy.
8. Bickel, W. K., & Amass, L. (1995). Buprenorphine treatment of opioid dependence: A review. Experimental and Clinical Psychopharmacology, 3, 477-489.
9. Bickel, W. K., Amass, L., Crean, J. P., & Badger, G. J. (1999). Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology, 146, 111-118.
10. Bickel, W. K., Amass, L., Higgins, S. T., Badger, G. J., & Esch, R. (1997). Effects of adding behavioral treatment to opioid detoxification with buprenorphine. Journal of Consulting and Clinical Psychology, 65, 803-810.
11. Bickel, W. K., Green, L., & Vuchinich, R. E. (1995). Behavioral economics. Journal of the Experimental Analysis of Behavior, 64, 257-262.
12. Bickel, W. K., Rizzuto, P., Zeilony, R. D., Klobas, J., Pangiosonlis, P., Mernit, R., & Knight, W. F. (1989). Combined behavioral and pharmacological treatment of alcoholic methadone patients. Journal of Substance Abuse, 1, 161-171.
13. Black, J. L., Dolan, M. P., Penk, W. E., Robinowitz, R., & DeFord, H. A. (1987). The effect of increased cocaine use on drug treatment. Addictive Behavior, 12, 289-292.
14. Carpenter, M. J., Chutuape, M. A., & Stitzer, M. L. (1998). Heroin snorters versus injectors: Comparison on drug use and treatment outcome in age-matched samples. Drug and Alcohol Dependence, 53, 11-15.
15. Carroll, K. M., Ball, S. A., Nich, C., O'Connor, P. G., Eagan, D. A., Frankforter, T. L., et al. (2001). Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: Efficacy of contingency management and significant other involvement. Archives of General Psychiatry, 58, 755-761.
16. Carroll, K. M., Sinha, R., Nich, C., Babuscio, T., & Rounsaville, B. J. (2002). Contingency management to enhance naltrexone treatment of opioid dependence: A randomized clinical trial of reinforcement magnitude. Experimental and Clinical Psychopharmacology, 10, 54-63.
17. Chapman, G. B. (1996). Temporal discounting and utility for health and money. Journal of Experimental Psychology: Learning, Memory, and Cognition, 22, 771-791.
18. Chatham, L. R., Hiller, M. L., Rowan-Szal, G. A., Joe, G. W., & Simpson, D. D. (1999). Gender differences at admission and follow-up in a sample of methadone maintenance clients. Substance Use and Misuse, 34, 1137-1165.
19. Chutuape, M. A., Silverman, K., & Stitzer, M. (1998). Survey assessment of methadone treatment services as reinforcers. American Journal of Drug and Alcohol Abuse, 24, 1-16.
20. Chutuape, M. A., Silverman, K., & Stitzer, M. (1999). Contingent reinforcement sustains post-detoxification abstinence from multiple drugs: A preliminary study with methadone patients. Drug and Alcohol Dependence, 54, 69-81.
21. Dolan, M. P., Black, J. L., Penk, W. E., Robinowitz, R., & DeFord, H. A. (1985). Contracting for treatment termination to reduce illicit drug use among methadone maintenance treatment failures. Journal of Consulting and Clinical Psychology, 53, 549-551.
22. Downey, K. K., Helmus, T. C., & Schuster, C. R. (2000). Treatment of heroin-dependent poly-drug abusers with contingency management and buprenorphine maintenance. Experimental and Clinical Psychopharmacology, 8, 176-184.
23. Higgins, S. T., Badger, G. J., & Budney, A. J. (2000). Initial abstinence and success in achieving longer term cocaine abstinence. Experimental and Clinical Psychopharmacology, 8, 377-386.
24. Higgins, S. T., Budney, A. J., Bickel, W. K., Foerg, F. E., Donham, R., & Badger, G. J. (1994). Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Archives of General Psychiatry, 51, 568-576.
25. Higgins, S. T., Budney, A. J., Bickel, W. K., Hughes, J. R., Foerg, F., & Badger, G. (1993). Achieving cocaine abstinence with a behavioral approach. American Journal of Psychiatry, 150, 763-769.
26. Higgins, S. T., Delaney, D. D., Budney, A. J., Bickel, W. K., Hughes, J. R., Foerg, F., & Fenwick, J. W. (1991). A behavioral approach to achieving initial cocaine abstinence. American Journal of Psychiatry, 148, 1218-1224.
27. Higgins, S. T. & Silverman, K. (Eds.). (1999). Motivating behavior change among illicit-drug abusers: Research on contingency management interventions. Washington, DC: American Psychological Association.
28. Higgins, S. T., Stitzer, M. L., Bigelow, G. E., & Liebson, I. A. (1986). Contingent methadone delivery: Effects on illicit-opiate use. Drug and Alcohol Dependence, 17, 311-322.
29. Iguchi, M., Stitzer, M. L., Bigelow, G. E., & Liebson, I. A. (1988). Contingency management in methadone maintenance: Effects of reinforcing and aversive consequences on illicit polydrug use. Drug and Alcohol Dependence, 22, 1-7.
30. Johnson, R. E., Cone, E. J., Henningfield, J. E., & Fudala, P. J. (1989). Use of buprenorphine in the treatment of opioid addiction: I. Physiologic and behavioral effects during a rapid dose induction. Clinical Pharmacology and Therapeutics, 46, 335-343.
31. Jones, H. E., Haug, N. A., Stitzer, M. L., & Svikis, D. S. (2000). Improving treatment outcomes for pregnant drug-dependent women using low-magnitude voucher incentives. Addictive Behaviors, 25, 263-267.
32. Kidorf, M., & Stitzer, M. L. (1996). Contingent use of take-homes and split dosing to reduce illicit drug use of methadone patients. Behavior Therapy, 27, 41-51.
33. Kosten, T. R. (1991). Client issues in drug abuse treatment: Addressing multiple drug abuse. In R. W. Pickens, C. G. Leukefeld, & C. R. Schuster (Eds.), Improving drug abuse treatment (NIDA Monograph No. 106, pp. 136-151). Washington, DC: U.S. Government Printing Office.
34. Leal, J., & Galanter, M. (1995). The use of contingency contracting to improve outcome in methadone maintenance. Substance Abuse, 16, 155-165.
35. Magura, S., Nwakeze, P. C., & Demsky, S. Y. (1998). Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction, 93, 51-60.
36. McCarthy, J. J., & Borders, O. T. (1985). Limit setting on drug abuse in methadone maintenance patients. American Journal of Psychiatry, 142, 1419-1423.
37. McLellan, A. T., Luborsky, L., Cacciola, J., Griffith, J., Evans, F., Barr, H., & O'Brien, C. (1985). New data from the Addiction Severity Index. Reliability and validity in three centers. Journal of Nervous and Mental Diseases, 173, 412-423.
38. Mendelson, J., Jones, R. T., Fernandez, I., Welm, S., Melby, A. K., & Baggott, M. J. (1996). Buprenorphine and naloxone interactions in opiate-dependence volunteers. Clinical Pharmacology and Therapeutics, 60, 105-114.
39. Nath, R. P., Upton, R. A., Everhart, E. T., Cheung, P., Shwonek, P., Jones, R. T., & Mendelson, J. E. (1999). Buprenorphine pharmacokinetics: Relative bioavailability of sublingual tablets and liquid formulations. Journal of Clinical Pharmacology, 39, 619-623.
40. Nathan, P. E., & Lansky, D. (1978). Common methodological problems in research on the addictions. Journal of Consulting and Clinical Psychology, 46, 713-726.
41. Nolimal, D., & Crowley, T. J. (1990). Difficulties in a clinical application of methadone-dose contingency contracting. Journal of Substance Abuse Treatment, 7, 219-224.
42. Nurco, D. N., Kinlock, T. W., & Hanlon, T. E. (1994). The nature and status of drug abuse treatment. Maryland Medical Journal, 43, 51-57.
43. Petry, N. M. (2000). A comprehensive guide to the application of contingency management procedures in clinical settings. Drug and Alcohol Dependence, 1, 9-25.
44. Petry, N. M., & Martin, B. (2002). Low-cost contingency management for treating cocaine- and opioid-abusing methadone patients. Journal of Consulting and Clinical Psychology, 70, 398-405.
45. Petry, N. M., Martin, B., Cooney, J. L., & Kranzler, H. R. (2000). Give them prizes, and they will come: Contingency management for treatment of alcohol dependence. Journal of Consulting and Clinical Psychology, 68, 250-257.
46. Petry, N. M., Martin, B., & Finocche, C. (2001). Contingency management in group treatment: Demonstration project in an HIV drop-in center. Journal of Substance Abuse Treatment, 21, 89-96.
47. Petry, N. M., Tedford, J., Austin, M., Nich, C., Carroll, K., M., & Rounsaville, B. J. (2004). Prize reinforcement contingency management for treating cocaine users: How low can we go, and with whom? Addiction, 99, 349-360.
48. Piotrowski, N. A., Tusel, D. J., Sees, K. L., Reilly, P. M., Banys, P., Meek, P., & Hall, S. M. (1999). Contingency contracting with monetary reinforcers for abstinence from multiple drugs in a methadone program. Experimental and Clinical Psychopharmacology, 7, 339-411.
49. Preston, K. L., Silverman, K., Umbricht, A., DeJesus, A., Montoya, I. D., & Schuster, C. R. (1999). Improvement in naltrexone treatment compliance with contingency management. Drug and Alcohol Dependence, 1, 127-135.
50. Rowan-Szal, G., Joe, G. W., Chatham, L. R., & Simpson, D. D. (1994). A simple reinforcement system for methadone clients in a community-based treatment program. Journal of Substance Abuse Treatment, 11, 217-223.
51. Saxon, A. J., Calsyn, D. A., Kivlahan, D. R., & Roszell, D. K. (1993). Outcome of contingency contracting for illicit drug use in a methadone maintenance program. Drug and Alcohol Dependence, 31, 205-214.
52. Schmitz, J. M., Rhoades, H. M., Elk, R., Creson, D., Hussein, I., & Grabowski, J. (1998). Medication take-home doses and contingency management. Experimental and Clinical Psychopharmacology, 6, 162-168.
53. Selzer, M. L. (1971). The Michigan Alcoholism Screening Test: The quest for a new diagnostic instrument. American Journal of Psychiatry, 127, 1653-1658.
54. Silverman, K., Bigelow, G. E., & Stitzer, M. L., (1998). Treatment of cocaine abuse in methadone maintenance patients. In S. T. Higgins & J. L. Katz (Eds.), Cocaine abuse: Behavior, pharmacology, and clinical application (pp. 363-389). New York: Academic Press.
55. Silverman, K., Higgins, S. T., Brooner, R. K., Montoya, I. D., Cone, E. J., Schuster, C. R., & Preston, K. L. (1996). Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Archives of General Psychiatry, 53, 409-415.
56. Silverman, K., Wong, C. J., Higgins, S. T., Brooner, R. K., Montoya, I. D., Contoreggi, C., et al. (1996). Increasing opiate abstinence through voucher-based reinforcement therapy. Drug and Alcohol Dependence, 41, 157-165.
57. Simpson, C. A., & Vuchinich, R. E. (2000). Temporal changes in the value of objects of choice: Discounting, behavior patterns, and health behavior. In W. K. Bickel & R. E. Vuchinich (Eds.), Reframing health behavior change with behavioral economics (pp. 193-215). Mahwah, NJ: Erlbaum.
58. Stitzer, M. L., Bickel, W. K., Bigelow, G. E., Liebson, I. A. (1986). Effect of methadone dose contingencies on urinalysis test results of polydug-abusing methadone-maintenance patients. Drug and Alcohol Dependence, 18, 341-348.
59. Stitzer, M. L., & Kirby, K. C. (1991). Reducing illicit drug use among methadone patients. In R. W. Pickens, C. G. Leukefeld, & C. R. Schuster (Eds.), Improving drug abuse treatment (NIDA Monograph No. 106, pp. 178-203). Washington, DC: U.S. Government Printing Office.
60. Substance Abuse and Mental Health Services Administration. (2004). Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction (Treatment Improvement Protocol No. 40). Rockville, MD: U.S. Department of Health and Human Services.
61. Thaler, R. (1981). Some empirical evidence on dynamic inconsistency. Economic Letters, 8, 201-207.